This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019. The report brings you up-to-date information about major pharmaceutical and technology companies active in the field, state of the art and emerging next generation technologies, subject and economic terms of partnering deals and a pipeline analysis of product candidates including clinical experiences.
Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overview. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.
Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.
Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.
This report will show you that there are plenty of opportunities for players in the field, including major pharmas, technology providers and investors.
38 technology companies with T-cell and NK cell engaging bispecific antibody technologies are analyzed regarding their:
In house established technologies to redirect T-cells and NK cells or engage cotimulatory molecules;
Emerging technologies to generate bispecifics with longer half-life, greater safety, higher efficacy and to target intracellular targets via peptide MHC complexes;
In-house product candidates in development (technology used, construct, target, indication, R&D phase).
The profiles of 58 clinical stage and 25 non-clinical development stage T-cell and NK cell engaging bispecific antibodies form the basis of:
Competitor analysis for a given target
Description of popular targets and bispecific antibody technologies
Discussion of product candidates from emerging next generation technologies
Learnin from clinical experience in hematologic and solid tumor indications.
So far, the attrition rate of T-cell and NK cell engaging antibodies is relatively low (12%). This report identified the terminated bispecific T-cell engager projects and the reasons for discontinuation.
This report also analyzes the financial maturity of technology companies and their specific sources of funding. Overall, raising money for bispecific T-cell and NK cell engagers is no fundamental problem.
What will you find in the report?
Profiles of 56 companies active in the field;
Comprehensive description and analysis of 38 established or emerging T-cell or NK-cell engaging antibody technologies;
Profiles of one approved, 89 T-cell or NK-cell engaging bispecific antibodies in all phases of development, and analysis of eight discontinued bispecific T-cell engagers;
Technology selection and preferences of major pharma;
Key characteristics of technologies with clinical stage drug candidates;
Emerging alternative bi- and trispecific formats;
Target selection and competition of drug candidates;
Competitive evaluation of clinical experience with bispecific T-cell and NK cell engagers;
Economic terms of collaboration and licensing deals;
Sources of financing.
Key Topics Covered
1 Executive Summary
2 Introduction
3 Stakeholder and Technology Analysis of Major Pharmaceutical Companies
4 Stakeholder and Technology Analysis of Technology Companies 4.1 Technology Companies with Ig-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies 4.2 Technology Companies with Fc-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies 4.3 Technology Companies with Binder-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies 4.4 Technology Companies with Special T-cell or NK Cell Engaging Bispecific Antibody Technologies
5 Pipeline Analysis of T-Cell and NK Cell Engaging Bispecific Antibodies 5.1 Tumor Targeting & Effector Cell Engagement 5.2 Clinical Experience with BCMA-Targeted T-Cell Engaging Bispecific Antibodies 5.3 Clinical Experience with CD33-Targeted T-Cell Engaging Bispecific Antibodies 5.4 Clinical Experience with CD20-Targeted T-cell Redirecting Bispecific Antibodies 5.5 Clinical Experience with CD123-Targeted T-Cell Engaging Bispecific Antibodies 5.6 Clinical Experience with PSMA-Targeted T-Cell Engaging Bispecific Antibodies 5.7 Clinical Experience with Other Solid Tumor Targeted T-Cell Engaging Bispecific Antibodies 5.8 Clinical Experience with Other Blood Cancer Targeted T-Cell Engaging Bispecific Antibodies 5.9 Discontinued Clinical Stage T-Cell Redirecting Bispecific Antibodies
6 Sources of Financing and Partnering Deals of Technology Companies
7 Company Profiles 7.1. Major Pharmaceutical Companies with Bispecific T-Cell or NK Cell Engaging Antibodies 7.2 Technology Companies with Ig-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies 7.3 Technology Companies with Fc-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies 7.4 Technology Companies with Binder-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies 7.5 Technology Companies with Special Bispecific T-Cell or NK Cell Engaging Antibody Technologies
AbbVie
Abpro
Adimab
Affimed Therapeutics
Alligator Bioscience
Amgen
Amphivena Therapeutics
Aptevo Therapeutics
Arbele
Astellas Pharma
AstraZeneca
BenHealth Biopharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Crescendo Biologics
CytomX Therapeutics
Dragonfly Theraputics
Eli Lilly
GEMoaB Monoclonals
Generon
Genmab
GlaxoSmithKline
Glenmark Pharmaceuticals
GT Biopharma
Harpoon Therapeutics
IGM Biosciences
Immatics Biotechnologies
Immunocore
Innate Pharma
Inovio Pharmaceuticals
Janssen
Lava Therapeutics
MacroGenics
Maverick Therapeutics
Merck & Co.
Merus
Mogam Institute for Biomedical Research (MIBR)
Molecular Partners
NJCTTQ
Novartis
Numab
Pfizer
Pieris Pharmaceuticals
PsiOxus Therapeutics
Regeneron Pharmaceuticals
Revitope Oncology
Roche
Sanofi
Servier
Takeda Pharmaceutical Co.
TeneoBio
VBL Therapeutics
Xencor
YZY Biopharma
Zymeworks
8 Technology Profiles 8.1 IG-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies 8.2 FC-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies 8.3 Binder Only-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologie 8.4 Novel Special T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Immune Disorders Drugs, Oncology Drugs
Related Links:
Author: Copyright GlobeNewswire, Inc. 2016. All rights reserved. You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.
Real-time